Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NIH-funded Institutional Training Programs in Colleges and Schools of Pharmacy.

American journal of pharmaceutical education·2026
Same author

Utilization of adjunctive anti-seizure medications to facilitate chronic benzodiazepine discontinuation.

The mental health clinician·2026
Same author

A qualitative analysis of pharmacy educator and recent graduates' perceptions regarding declining NAPLEX first-time pass rates.

Currents in pharmacy teaching & learning·2026
Same author

Strategies to Address Communication Vulnerability in Adult Intensive Care Units Through Practice, Environment, and Policy Modifications.

Journal of nursing care quality·2026
Same author

A Deimplementation Framework for Curricular Hoarding in Pharmacy Education.

American journal of pharmaceutical education·2026
Same author

Exploring curriculum gaps in pharmacy education in Nepal: A pilot study and recommendations for reform.

Currents in pharmacy teaching & learning·2026

Related Experiment Video

Updated: Jul 14, 2026

Setup and Execution of the Rapid Cycle Deliberate Practice Death Notification Curriculum
04:36

Setup and Execution of the Rapid Cycle Deliberate Practice Death Notification Curriculum

Published on: August 5, 2020

Board certification of pharmacy residency program directors.

Noelle E Daugherty1, Melody Ryan, Frank Romanelli

  • 1University of Kentucky HealthCare, Lexington, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|June 27, 2007
PubMed
Summary

More than one third of pharmacy residency program directors (RPDs) hold Board of Pharmaceutical Specialties (BPS) certification, driven primarily by professional development. New accreditation standards did not significantly motivate certification, though most RPDs already meet them.

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Mechanical Ventilation Boot Camp Curriculum
07:36

Mechanical Ventilation Boot Camp Curriculum

Published on: March 12, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

Setup and Execution of the Rapid Cycle Deliberate Practice Death Notification Curriculum
04:36

Setup and Execution of the Rapid Cycle Deliberate Practice Death Notification Curriculum

Published on: August 5, 2020

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Mechanical Ventilation Boot Camp Curriculum
07:36

Mechanical Ventilation Boot Camp Curriculum

Published on: March 12, 2018

Area of Science:

  • Pharmacy Practice
  • Continuing Professional Development
  • Residency Education

Background:

  • Board of Pharmaceutical Specialties (BPS) certification is increasingly recognized in pharmacy.
  • Understanding the prevalence and drivers of BPS certification among pharmacy residency program directors (RPDs) is crucial for professional development and accreditation.
  • The evolving landscape of pharmacy residency accreditation, particularly the American Society of Health-System Pharmacists (ASHP) post-graduate year 2 (PGY2) standards, necessitates an examination of RPDs' certification status.

Purpose of the Study:

  • To assess the extent of BPS certification among RPDs.
  • To identify RPDs' motivations and incentives for obtaining BPS certification.
  • To determine the proportion of RPDs meeting new ASHP PGY2 residency standards for board certification.
  • To explore relationships between RPD characteristics and BPS certification.

Main Methods:

  • An electronic questionnaire with 35 items was administered to RPDs.
  • Data collected included practice setting, job title, faculty rank, education, training, practice experience, RPD tenure, and certifications obtained.
  • Survey responses were analyzed to identify trends in BPS certification.

Main Results:

  • A total of 327 out of 717 RPDs completed the survey.
  • Over one-third of surveyed RPDs held BPS certification, exceeding the rate reported in the BPS directory.
  • RPDs in PGY2 programs and those who completed an ASHP-accredited specialized residency program were more likely to be BPS certified.

Conclusions:

  • Professional and personal development emerged as the primary motivators for RPDs seeking BPS certification.
  • New pharmacy residency accreditation standards were not a significant driver for RPDs to obtain certification.
  • A substantial majority (71%) of RPDs requiring board certification under new standards already met the criteria.
  • RPDs in academic settings or critical care specialties demonstrated higher rates of BPS certification compared to those in community practice or practice management.